ReviewNanomaterials (Basel, Switzerland)2026
Tetrahedral DNA Nanostructures: A Structural-Family-Aware Review from Computational Design and Biological Stability to Translational Nanomedicine.
Review in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
DNA has evolved from a carrier of genetic information into a programmable material for constructing nanoscale architectures with precise structural and functional control. Among these systems, tetrahedral DNA nanostructures (TDNs) comprise at least two experimentally distinct structural families: small scaffold-free tetrahedra assembled from a few synthetic oligonucleotides, often termed tetrahedral framework nucleic acids (tFNAs), and larger scaffolded or wireframe tetrahedral DNA-origami objects. This review integrates assembly principles, computational and sequence-level design, physicochemical stability, fabrication, structural validation, biological performance, and translational evidence while keeping these two families analytically separate. For few-strand TDNs, particular attention is given to ionic conditions, pH, temperature, serum and nuclease exposure, cellular uptake, targeting aptamers, and delivery of drugs and regulatory nucleic acids; scaffolded tetrahedral origami is discussed where its routing, mechanics, manufacturing, or larger spatial capacity are directly relevant. Recent in vivo studies provide evidence for tissue distribution, transdermal delivery, and short-term biocompatibility of selected few-strand TDN formulations, but the translational evidence remains predominantly preclinical. Rather than positioning TDNs as universally superior nanocarriers, this review emphasizes architecture-specific evidence, quantitative experimental conditions, and the limits of transferring conclusions between structural families. Progress toward translational nanomedicine will require validated design rules, matched-condition benchmarking, pharmacokinetic and biodistribution studies, scalable manufacturing, standardized quality attributes, and rigorous safety assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.